Advertisement
Canada markets close in 2 hours 25 minutes
  • S&P/TSX

    21,853.30
    -20.42 (-0.09%)
     
  • S&P 500

    5,036.03
    -35.60 (-0.70%)
     
  • DOW

    38,046.39
    -414.53 (-1.08%)
     
  • CAD/USD

    0.7314
    +0.0017 (+0.23%)
     
  • CRUDE OIL

    82.80
    -0.01 (-0.01%)
     
  • Bitcoin CAD

    88,177.30
    -800.35 (-0.90%)
     
  • CMC Crypto 200

    1,392.47
    +9.90 (+0.72%)
     
  • GOLD FUTURES

    2,341.60
    +3.20 (+0.14%)
     
  • RUSSELL 2000

    1,972.69
    -22.74 (-1.14%)
     
  • 10-Yr Bond

    4.7040
    +0.0520 (+1.12%)
     
  • NASDAQ

    15,556.17
    -156.58 (-1.00%)
     
  • VOLATILITY

    16.42
    +0.45 (+2.82%)
     
  • FTSE

    8,078.86
    +38.48 (+0.48%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • CAD/EUR

    0.6810
    -0.0009 (-0.13%)
     

Merck quarterly profit up 18 percent

A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines. REUTERS/Jeff Zelevansky

(Reuters) - Merck & Co Inc (NYSE:MRK - News) reported an 18 percent rise in quarterly profit, driven by higher sales of diabetes drug Januvia and heart drug Zetia.

Net income attributable to Merck rose to $1.12 billion, or 40 cents per share, in the first quarter, from $953 million, or 33 cents per share, a year earlier.

Revenue dipped about 1 percent to $9.31 billion.

(Reporting by Natalie Grover in Bengaluru; Editing by Savio D'Souza)